Healios KK (JP:4593) has released an update.
Healios KK has postponed finalizing its development and commercialization agreement with Nobelpharma for MultiStem, a stem cell therapy for ARDS, from September 2024 to January 2025. This delay will allow further discussions in light of recent developments, including a positive Phase 2 study in Japan and ongoing preparations for a global Phase 3 trial. The company asserts that this rescheduling will not affect its consolidated financial results for the fiscal year ending December 31, 2024.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.